Table 1.
Characteristics of HCV-HIV Coinfected and HCV Monoinfected Transplant Recipients
| HCV-HIV (N=89) | HCV (N=235) | P Value | |
|---|---|---|---|
| Recipient Characteristics | |||
| Age – yr (median [IQR]) | 49 [44, 53] | 54 [51, 60] | <.0001 |
| Male Gender – no. (%) | 67 (75) | 166 (71) | 0.49 |
| Caucasian Race – no. (%) | 58 (65) | 126 (54) | 0.08 |
| BMI at Listing (median [IQR]) | 25 [23–28] | 28 [25–32] | <.0001 |
| MELD at LT (median [IQR]) | 20 [15–27] | 20 [15–28] | 0.80 |
| Hepatocellular Carcinoma – no. (%) | 30 (34) | 73 (31) | 0.69 |
| HCV Genotype 1/4/other – no. (%) | 71 (80) | 192 (82) | 0.85 |
| HBV Coinfection – no. (%) | 5 (6) | 2 (1) | 0.02 |
| Donor/Transplant Characteristics | |||
| Donor Age – yr (median [IQR]) | 37 [24, 49] | 42 [30, 53] | 0.07 |
| Black Donor Race – no. (%) | 10 (11) | 36 (15) | 0.38 |
| Living Donor – no. (%) | 1 (1) | 15 (6) | 0.08 |
| Donor Risk Index (DRI) - median [IQR] | 1.31 [1.15–1.62] | 1.42 [1.21–1.77] | 0.08 |
| Cold Ischemia Time – hours (median [IQR]) | 7.6 [5.8, 9.9] | 8.0 [6.2, 10.1] | 0.23 |
| Non-heart Beating Donor – no. (%) | 15 (17) | 8 (4) | 0.0002 |
| Warm Ischemia Time – min. (median [IQR]) | 41 [36, 55] | 21 [13, 26] | 0.001 |
| Anti-HCV Positive Donor – no. (%) | 12 (13) | 26 (11) | 0.14 |
| HBV Core Antibody + Donor – no. (%) | 12 (13) | 24 (10) | 0.16 |
| Combined Kidney-Liver Transplant – no. (%) | 8 (9) | 17 (7) | 0.64 |
| Split/Partial Transplant – no. (%) | 1 (1) | 2 (1) | 1.00 |
| Post-Transplant Characteristics | |||
| Initial calcineurin inhibitor Use – no. (%) | <.0001 | ||
| Cyclosporine | 31 (35) | 23 (10) | |
| Tacrolimus | 52 (58) | 188 (80) | |
| None | 6 (7) | 9 (4) | |
| Not reported | 15 (6) | ||
| HCV Treatment – no. (%) | 37 (42) | 57 (24) | 0.002 |
| Follow-up Post-LT – yr (median [IQR]) | 1.8 [0.7, 3.4] | 2.0 [1.1, 3.4] | 0.51 |
| HIV-Specific Characteristics | |||
| CD4+ T-Cell (cells/mm3) a – median [IQR] | 283 [187–408] | ||
| HIV RNA Undetectable a – no. (%) | 78 (88) | ||
| On Antiretrovirals within 1st Week Post-LT (%) | 71 (80) | ||
| Antiretroviral Therapyb – no. (%) | |||
| Protease Inhibitor (PI) | 45 (51) | ||
| Non-Nucleoside (NNRTI) | 22 (25) | ||
| PI & NNRTI | 4 (4) | ||
| Nucleosides only | 15 (17) | ||
| None | 3 (3) | ||
a
Most recent pre-transplant value, within 16 weeks of transplant.
b
Most recent pre-transplant: The PI, NNRTI, PI and NNRTI, and Nucleosides only regimens included at least two nucleoside analogues (except for seven that included a single nucleoside analogue). Of the 22 NNRTI-based regimens, 18 included efavirenz, 3 nevirapine and 1 etravirine. Two PI-based regimens included raltegravir and one PI-based regimen included enfuvirtide as well.